By Abdulrahman Aliagan writes from Okereke Diary
When thousands of HIV researchers, clinicians, policymakers and advocates gathered in Rio de Janeiro, Brazil, for AIDS 2026, one Nigerian pharmacist brought a perspective rooted not in a laboratory experiment, but in the everyday realities of HIV care in Africa.
Melody Okereke, a Nigerian pharmacist and HIV/AIDS implementation science researcher, presented research examining antiretroviral treatment outcomes using a decade of routine clinical data from a high-volume HIV treatment clinic in southern Nigeria.
His presentation at the 26th International AIDS Conference placed an important question at the centre of the global HIV conversation: when treatment guidelines change, how quickly do those changes translate into measurable improvements for patients receiving care in real-world health systems?
The question is particularly significant for countries such as Nigeria, where HIV programmes operate at considerable scale and must translate evolving international and national recommendations into everyday clinical practice.
Beyond the clinical trial
Modern HIV treatment has transformed the lives of millions of people living with the virus. Antiretroviral therapy can suppress HIV to very low levels, helping patients live longer and healthier lives while dramatically reducing the risk of transmission.
But establishing that a treatment works is only one part of the equation.
According to Okereke, the more difficult challenge begins when evidence from controlled clinical studies has to be translated into routine healthcare settings.
This is where implementation science becomes critical.
Clinical trials are designed to determine whether an intervention works under carefully controlled conditions. Routine health systems, however, operate in a far more complex environment, shaped by drug availability, patient retention, healthcare-worker capacity, laboratory services, adherence, financing and changing treatment policies.
Okereke’s research therefore looked beyond a simple comparison of treatment regimens. By analysing ten years of clinical information, the study examined how changes in antiretroviral treatment were associated with virological outcomes as treatment recommendations evolved.
At the heart of the analysis was viral suppression, one of the most important indicators of successful HIV treatment.
What happens after policy changes?
For HIV programmes, changing treatment guidelines can be a major undertaking.
New recommendations may require healthcare workers to be trained, patients to be transitioned to different medicines, procurement and supply systems to be adjusted, pharmacy records to be updated and laboratory monitoring to be maintained.
The existence of a new recommendation, therefore, does not automatically mean that its benefits will immediately appear in patient outcomes.
This distinction gives routine programme data enormous value.
HIV treatment facilities routinely generate information through patient treatment histories, pharmacy records, viral-load testing and other clinical monitoring systems. Yet much of this information can remain underused beyond immediate patient management and programme reporting.
Okereke’s work demonstrates how those existing data can be examined over time to answer broader questions about whether policy changes are producing the expected results.
Rather than waiting for a new research project to generate fresh evidence, health programmes can use information they already possess to identify trends, assess implementation and detect areas where patients may not be experiencing the benefits anticipated by policy changes.
The African evidence gap
The presentation also speaks to a broader issue in global health research: the importance of evidence generated from African health systems.
Much of the scientific evidence used to shape global treatment recommendations emerges from carefully controlled studies. Such research remains indispensable, but the conditions under which clinical trials are conducted can differ substantially from those found in routine healthcare facilities.
African treatment programmes operate within their own realities.
Patients may face transportation difficulties, economic pressures and interruptions in care. Health facilities may contend with staffing constraints, laboratory capacity limitations and medicine supply challenges. At the same time, national programmes must respond to changing guidelines while maintaining continuity of treatment for millions of people.
Data generated from these environments can therefore provide a different and complementary perspective.
For Okereke, African clinical data should not simply be regarded as information about local programmes. They can contribute to the global understanding of how HIV interventions perform when implemented at scale and under real-world conditions.
AIDS 2026 and the implementation challenge
The broader discussions at AIDS 2026 provided a timely backdrop to the Nigerian research.
As the HIV response enters a new phase, scientific progress is increasingly being accompanied by questions about affordability, sustainability, equitable access and health-system capacity.
New treatment options and prevention technologies continue to emerge, but their population-level impact depends heavily on whether health systems can deliver them consistently.
For countries facing financial and operational pressures, the question is becoming increasingly urgent: how can programmes preserve the gains of the HIV response while ensuring that new scientific advances reach the people who need them?
That challenge makes implementation science increasingly relevant.
The success of an HIV intervention cannot be measured only by what happens in a controlled research environment. It must also be assessed by what happens in ordinary clinics, among ordinary patients, over months and years.
From evidence to impact
Okereke’s research ultimately points to a simple but consequential principle: adopting a new treatment recommendation should not be the end of the process.
It should be the beginning of another phase of evidence gathering.
Health authorities and HIV programmes need systems capable of monitoring what happens after policies are introduced, identifying whether patients are achieving expected outcomes and understanding why gaps emerge where they do.
As Okereke puts it:
“The important question is not only whether a treatment is effective. We also need to understand whether the health system can deliver it consistently and whether patients experience the expected outcomes in routine practice.”
That perspective is particularly relevant to Nigeria, where the scale of the HIV response means that even relatively small implementation gaps can affect large numbers of people.
It also reinforces the importance of strengthening routine health information systems—not merely as administrative tools, but as instruments for learning and improving healthcare delivery.
The road ahead
The HIV response has come a long way, but AIDS 2026 demonstrated that scientific innovation alone will not determine the next chapter of the epidemic.
The ability to translate innovation into sustained population-level impact will depend increasingly on health systems.
For African countries, that means ensuring that new treatment and prevention recommendations are accompanied by adequate monitoring, reliable service delivery, continuous evaluation and the capacity to respond when implementation falls short.
For researchers such as Melody Okereke, the data needed to answer some of these questions may already be sitting inside the health system—in clinic records, pharmacy histories and viral-load results accumulated over years.
The challenge is to turn those records into evidence, and evidence into action.
From a high-volume HIV clinic in southern Nigeria to an international scientific platform in Rio de Janeiro, Okereke’s research has brought that message into sharper focus: the future of HIV care will not depend only on discovering what works, but on understanding how to make what works succeed in the real world.